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Statins and diabetic 
nephropathy
Statins, the wonder drugs of the current 
age, have many described eff ects, includ-
ing reduction of cholesterol biosynthe-
sis through inhibition of HMG-CoA 
reductase. Researchers have suggested 
that statins also reduce morbidity 
from diabetic nephropathy. As they 
report in this issue, Fujii et al. studied 
the role of statins in experimental dia-
betic nephropathy using db/db mice, 
a rodent model of type 2 diabetes. Th e 
statin reduced albuminuria, mesangial 
expansion, and expression of transform-
ing growth factor-β. It also reduced the 
expression of NOX4, a subunit of the 
NAPH oxidase long thought to be the 
proximate cause of reactive oxygen spe-
cies in the kidney. Oxidative damage is 
now the villain in many infl ammatory 
and fibrotic diseases. The beneficial 
effect of statins would be a welcome 
addition to the few therapies available 
for these diseases. Yet, the question 
remains of whether statins act by 
inhibiting lipid metabolism, or whether 
they work on a completely independent 
pathway, and reduced oxidative kidney 
damage is an interesting side eff ect. See 
page 473.
Erythropoietin and 
podocytes
Recent studies have shown that eryth-
ropoietin has beneficial effects on a 
variety of ischemic conditions, includ-
ing ischemic renal injury. Researchers 
have discovered a new receptor, which 
might mediate these eff ects. Logar et 
al. present new fi ndings on the eff ect 
of darbepoetin, a long-acting erythro-
poietin analogue, on the development 
and progression of puromycin-induced 
nephrotic syndrome. Th e drug reduced 
proteinuria and led to normalization of 
some markers of podocyte injury, such 
as the costimulatory molecule B7.1 and 
desmin. It also normalized the fusion of 
foot processes, long known to be a char-
acteristic of minimal-change disease. 
Whether the eff ect of darbepoetin was 
mediated by the erythrogenic receptor 
or the new receptor remains to be dis-
covered. See page 489.
ABC of epidemiology
It is impossible to address modern 
medicine without thinking in terms 
of epidemiology. Its status in biomedi-
cal research is as an abstract group of 
ideas that form an analytical tool to set 
boundaries and allow ‘correct’ thinking 
about specified and well-articulated 
problems. Epidemiology in biomedical 
research is independent of the mecha-
nism of the phenomena being studied; 
this is its greatest strength and weak-
ness. Epidemiology does not generate 
new discoveries of pathophysiology or 
etiology (even in the case of smoking 
and lung cancer), yet it is necessary for 
clear thinking about medical questions. 
Without epidemiology, centuries of 
poorly-thought-out anecdotal evidence 
would befuddle the unwary. Behind 
every clinical decision, there is always 
the background of disease incidence, 
risk factor analysis, outcome analysis of 
a therapeutic decision, and much more. 
Most physicians are conversant with the 
vernacular language of epidemiology 
but may not actually know what the ter-
minology means. Carmine Zoccali has 
edited a series of articles that address 
important topics in the epidemiology of 
renal disease.  Th e fi rst in the series can 
be found on page 411.  Th ese short arti-
cles will help you refresh your knowl-
edge and improve your understanding 
of the subject without being overloaded 
with dreaded equations.
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